Two-year safety and virologic efficacy of maraviroc in treatment- experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 5, 2010, Pages 558-564

  Hardy, W David ^a   Gulick, Roy M ^b   Mayer, Howard ^c   Fätkenheuer, Gerd ^d   Nelson, Mark ^e   Heera, Jayvant ^c   Rajicic, Natasa ^f   Goodrich, James ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f PFIZER INC   (United States)

Author keywords

HIV; host based therapies; long term safety; maraviroc; treatment experienced

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR5; TRIAZOLES;

EID: 78650205571     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ee3d82     Document Type: Article

References (25)

1. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemo-kine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721-4732.
2. Pfizer Inc. Selzentry (maraviroc) prescribing information. Available at: http://www.selzentry.com/splashpage.aspx. Accessed November 16, 2009.
3. Gulick R, Lalezari J, Goodrich J, et al. for the MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
4. Fatkenheuer G, Nelson M, Lazzarin A, et al. for the MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-1555.
5. Ayoub A, Goodrich J, van der Ryst E, et al. Adverse event profile of maraviroc in treatment-experienced patients infected with R5 HIV-1. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; October 25-28, 2008; Washington, DC. Abstract H-1264.
6. Ayoub A, Goodrich J, Tressler R, et al. Incidence of infections in treatment-experienced patients infected with R5 HIV-1 in the MOTIVATE studies of maraviroc in combination with optimized background therapy. Presented at: Ninth International Congress on Drug Therapy in HIV Infection; November 9-13, 2008Glasgow, United Kingdom. Abstract P154.
7. Fry J.FDA/FCHR collaborative public meeting on long-term safety concerns associated with CCR5 antagonist development. Available at: www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4283b1-02-03-FDA-draftreport.pdf. Accessed August 14, 2009.
8. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008;52:858-865.
9. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196:304-312.
10. Tsibris AM, Paredes R, Chadburn A, et al. Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009;48:642-649.
11. Valdez H, Lewis M, Delogne C, et al. Weighted OBT susceptibility score (wOBTSS) is a stronger predictor of virologic response at 48 weeks than baseline tropism result in MOTIVATE 1 and 2. Presented at: 48th ICAAC/ IDSA 46th Meeting; October 25-28 2008; Washington, DC. Abstract H-1221.
12. Jubb R, Lewis M, Simpson P, et al. CCR5-tropic resistance to maraviroc is uncommon even among patients on functional MVC monotherapy or with ongoing low-level replication. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract M199.
13. Heera J, Ive P, Botes M, et al. The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract TUAB103.
14. Gomez-Reino JJ, Pablos JL, Carreira PE, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 1999;42:989-992.
15. Pokorny V, McQueen F, Yeoman S, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis. 2005;64:487-490.
16. Zapico I, Coto E, Rodriguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. J Rheumatol. 2000;27:2308-2311.
17. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54:1157-1161.
18. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2: 1240-1243.
19. de Roda Husman A, Koot M, Cornelisson M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 1997;127:882-890.
20. Dean M, Lacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-D32 mutation. Cancer Res. 1999;59:3561-3564.
21. Meyer L, Magierowska M, Hubert J-B, et al. CCR5 D32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;180:920-924.
22. Ashton LJ, Stewart GJ, Biti R, et al. Heterozygosity for CCR5-Delta32 but not CCR2b-64I protects against certain intracellular pathogens. HIV Med. 2002;3:91-96.
23. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203: 35-40.
24. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis. 2008;197:262-265.
25. Pulendran B, Miller J, Querec TD. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198:500-507.